T he HIV antiretroviral medication has revolutionized the early treatment options for individuals diagnosed with HIV infection, the virus that causes AIDS. Furthermore.jt has led to the availability of post-exposure prophylaxis (PEP) medication for individuals exposed to mv positive blood and certain body fluids via workplace exposures. Since the onset of the AIDS epidemic in the early 1980s, AIDS mortality rates in the United States have declined significantly (Healthcommunities, 2003) . AIDS has been redefined from a condition that inevitably leads to fairly rapid death, to a disease with which many individuals in the United States are living. The introduction of highly active antiretroviral therapy (HAART) in the form of a two or three drug daily regimen, has not
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only effected management for mv infected individuals, but holds vast implications for occupational health professionals managing health care workers exposed to infectious blood and body fluids.
The Centers for Disease Control and Prevention's (CDC) published guidelines contend that the risk of health care personnel obtaining HIV infection from a percutaneous stick is .3%, and from a mucous membrane splash is .09% (Ippolito, 1993) . Although these rates of infection are low, evidence weighs heavily on introducing PEP within 24 to 48 hours after an exposure to a patient who is an mv positive source, a patient with HIV risk factors, or an exposure where the source patient is unknown but contact with patients who are HIV positive is high. Early intervention with PEP for 4 weeks post-exposure may prevent HIV infection by blocking spread of the virus to target cells or into the lymph system (CDC, 2001a) .
Although these recommendations serve as practice criteria for occupa-tional health practitioners, the decision making process when considering PEP requires careful analysis of a host of factors that are, at times, ambiguous. The CDC guidelines are aimed at simplifying this decision making process; however, the occupational health clinician, working in collaboration with an infectious disease physician consultant, must broadly understand the historical and physiological rationale for considering antiretroviral treatment.
Weighing the risk versus benefit of treatment, given the plethora of side effects associated with PEP medication, is an essential component of management. Occupational health professionals are responsible for: • Understanding and assessing the exposure.
• Collaborating with infectious disease experts in relation to when and what kind of PEP should be used. • Educating the health care worker about side effects of the medication. • Monitoring the employee appropriately for the duration of treatment with PEP.
Understanding the role of pharmacologic treatment for HIV infection, and subsequently medication use as PEP post-exposure to blood and body fluid is an imperative piece of the occupational health clinician's knowledge base. The year 1987 marks the introduction of the first group of antiretroviral drugs, known as nucleoside reverse transcriptase inhibitors (NRTIs). This class of drug works by preventing reverse transcriptase, an enzyme necessary for HIV infection to attack healthy cells and reproduce itself in the body (Avert, 2(03). Azidothymidine, better known as AZT (zidovudine, Retrovir), is the first drug from this class and the first anti-HIV drug approved by the Food and Drug Administration (FDA) (Aegis, 2(01). Other NRTIs received FDA approval later, and including (University of California, San Francisco [UCSFJ, 2(03):
• TFV (TDF, PMPA, Tenofovir).
The second group of antiretroviral medications is non-nucleoside reverse transcriptase inhibitors (NNRTIs). These drugs first appeared in 1996 with initial FDA approval of nevirapine (NVP, Viramune) (Aegis, 2(01), followed by delavirdine (DLV, Rescriptor), and efavirenz (EFV, Sustiva) (UCSF, 2(03). The NNRTIs block cell duplication by binding to the cell's reverse transcriptase, thereby blocking cell duplication at a different site than NRTIs. They are generally used less than NRTIs because they are associated with some serious dermatologic side effects, and clients develop drug resistance rapidly (Katz, 2(00) .
In 1995, the third type of antiretroviral medication, known as protease inhibitors (Pis), received FDA approval with the introduction of saquinavir (SQV, Invirase). Protease inhibitors are potent suppressors of HIV replication (Katz, 2(00 Mortality rates associated with AIDS dropped 70% in the years 1996 to 1998, and declined an additional 4% in 1999 (CDC, 200lc) . According to Garcia de Olalla (2002) , 3 year survival rates for HIV infected individuals adhering to triple therapy is 93.6%, double therapy is 77.8%, and for monotherapy is 76.1%. In one University of California, Los Angeles (UCLA) study, the amount of time from HIV infection to progression to AIDS was 63% longer than before HAART therapy was available (UCLA, 1998 Unlike many other clinical decision making dilemmas, the decision to use HAARTs for PEP therapy becomes complicated at times. Although the CDC provides descriptive information related to categorizing risk and whether or not to use a two to three drug regimen, the guidelines indicate the decision should be based on empirical data.
Deciding on appropriate medication is usually less complicated when a two drug regimen is indicated. The use of AZT and 3TC in a combined pill, such as Combivir, is a common choice. However, occupational clinicians must use caution when using this medication. Drug resistance to AZT is appearing more often, placing occupational health clinicians in positions where they should examine the HIV positive source patient's medical and medication history instead of quickly choosing Combivir. If the source patient's HIV status is unknown, but HIV risk is moderate to high, clinicians should be aware of recent regional outbreaks of resistant HIV infection and be comfortable seeking guidance from infectious disease experts when deciding on HAARTs other than Combivir. Side effects, including nausea and diarrhea, are common with Combivir. Clinicians should be cognizant that adverse reactions greatly effect adherence, and therefore readily prescribe anti-emetics and consider other two drug combinations such as 3TC and d4T (CDC, 200lb) .
The decision to use triple therapy should be thoughtful, with clinicians carefully examining the level of the exposure and weighing the risk versus benefits of treatment. The PIs are often used as the third drug and are associated with the development of new onset diabetes, diabetic ketoacidosis, hyperglycemia, dyslipidemia, and nephrolithiasis. A three drug regimen is indicated in severe percutaneous exposures from an HIV positive source patient, or in less severe exposures when the source patient has a high viral load. In instances of mucus membrane exposures, clinicians should consider a three drug regimen when the source patient has a high viral load and a large volume of blood or body fluid is involved. Indinavir (Crixivan) and Nelfinavir (Viracept) are commonly used protease inhibitors when a third drug is indicated. More recently, the use of Kaletra has gained favor as an alternative medication choice because it is better tolerated. It should be used with caution and with expert consultation. Kaletra interacts with many other drugs, causing serious adverse events. It may also diminish the effectiveness of oral contraceptives (CDC, 200lb) .
Monitoring and counseling the health care worker receiving PEP requires expertise as well as empathy. Laboratory testing for individuals receiving PEP should include a baseline complete blood count (CBC) and comprehensive metabolic profile with repeat testing 2 weeks post-therapy. If certain drugs have specific associated side effects, additional laboratory tests may be indicated. Health care workers with exposures warranting PEP are often emotional, anxious, and have many concerns. By educating health care workers, in-depth, about expected side effects, and about when immediate follow up is necessary, clinicians may alleviate some fear if adverse reactions occur.
Counseling related to avoidance of unprotected sexual conduct, donation of blood or blood products, avoidance of pregnancy and breastfeeding, avoidance of semen and tissue donation should be discussed openly, and all questions should be answered fully. Clinicians should emphasize that although statistics demonstrate a low risk of seroconversion related to percutaneous and mucus membrane exposures, completion of the 4 week 372 Clinical Rounds: Hospital Link PEP regimen is essential in minimizing the risk of HIV transmission. Occupational health professionals should partner with employees to modify medication as needed and continually encourage employees to complete PEP therapy.
The limitation of HAART is the enormous cost of the life saving medication, which makes it elusive to many outside the United States. As exciting as the advances are, one should not take for granted the reality that HN continues to devastate the world at large with high mortality rates, particularly in Sub-Saharan Africa, South Asia, and the former Soviet Union (Healthcommunities, 2003) . Treatment for HIV infection continues to evolve as researchers strive to redefine PEP from treatment with antiretroviral medication to introduction of an HIV vaccine. Such a possibility seems within reach when understanding the demonstrable gains in HIV and AIDS management from the 1980s to present.
